Genomics, proteomics and cancer: Specific ribosomal, mitochondrial, and tumor reactive proteins can be used as biomarkers for early detection of breast cancer in serum

Cancer Genomics and Proteomics

Volumn 2, Issue 1, 2005, Pages 1-24

  Fernandez Pol, J Alberto ^a,b,c   Hamilton, Paul D ^a   Klos, Dennis J ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^c Metalloproteomics   (United States)

Author keywords

Biomarkers; Breast cancer; Metallopanstimulin

Indexed keywords

BIOLOGICAL MARKER; CA 15-3 ANTIGEN; COMPLEMENT COMPONENT C3; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; GROWTH FACTOR; HAPTOGLOBIN; METALLOPANSTIMULIN; MITOCHONDRIAL PROTEIN; RECOMBINANT DNA; RIBOSOME PROTEIN; TAMOXIFEN; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AMINO ACID SEQUENCE; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER DIAGNOSIS; CONTROLLED STUDY; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; GENE EXPRESSION; GENE LIBRARY; GENOMICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; PROTEIN BLOOD LEVEL; PROTEOMICS; RELIABILITY; RIBOSOME; RIBOSOME SUBUNIT; SERUM; TISSUE CULTURE; WESTERN BLOTTING;

EID: 20344387010     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. Landis SH, Murray T, Bolden S and Wingo PA: Cancer statistics, 1998. CA, Canc. J Clinic 48: 6-29, 1998.
2. Hortobagyi GN, and Buzdar AU: Current status of adjuvant systemic therapy for primary breast cancer: Progress and controversy. CA, Canc J Clinic 45: 199-226, 1995.
3. Smart CR, Byrne C, Smith RA, Garfinkel L, Letton AH, Dodd GD and Beahrs OH: Twenty-year follow-up of breast cancers diagnosed during breast cancer demonstration project. CA, Canc J Clinic 47: 134-149, 1997.
4. Leitch AM, Dodd GD, Costanza M, Linver M, Pressman P, McGinnis L and Smith RA: American cancer society guidelines for the early detection of breast cancer: Update 1997. CA, Canc J Clinic 47: 150-153, 1997.
5. Gayther SA and Ponder BA: Mutations of the BRCA1 and BRCA2 genes and the possibilities for predictive testing. Mol Med Today 3: 168-174, 1997.
6. Balducci L, Silliman RA and Baekey P: Breast cancer: an oncological perspective - part 1. In: Balducci L, Lyman GH and Ershler WB (eds), Comprehensive geriatric oncology. Harwood Academic Publishers, Amsterdam, 1998, pp 629-660.
7. Morgan MWE, Warren R and Querci della Rovere G (eds): Early breast cancer: from screening to multidisciplinary management. Hardwood Academic Publishers, Amsterdam, 1998, pp. 17-285.
8. Schwartz MK: Cancer markers: In: DeVita Jr VT, Hellman S and Rosenberg SA (eds): Cancer: principles and practice of oncology, JB Lippincott Co, Philadelphia, 1993, pp. 531-542, 4th Ed. Vol. 1.
9. Klapdor R (ed): Abstracts of the eighth international Hamburg symposium on tumor markers. Anticancer Res 17: 4173-4242, 1997.
10. Blijlevens NM, Oosterhuis WP, Oosten HR and Mulder NH: Clinical value of TPS, CEA and CA 15-3 in breast cancer patients. Anticancer Res 75: 2711-2716, 1995.
11. Bombardieri E, Seregni, E, Giani D, Bogni A, Gion M and Buraggi GL: Heterogeneity and specificity of cancer associated mucins. J Nucl Med Allied Sci 34: 163-169, 1990
12. Busetto M, Vianello L, Franceschi R and Bolzan M: CA 15-3 value and neoplastic disease predictivity in the follow-up for breast cancer. Tumour Biol 16: 243-253, 1995.
13. Caponigro F, Iaffaioli RV, Pagliarulo C, De Placido S, Frasci G, Ungaro B, Matano E and Bianco AR: CA 15-3 in human breast cancer. Comparison with tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA). Intl J Biol Markers 5: 73-76, 1990.
14. Coveney EC, Geraghty JG, Sherry F, McDermott EW, Fennelly JJ, O'Higgins NJ and Duffy MJ: The clinical value of CEA and CA 15-3 in breast cancer management. Int J Biol Markers 10: 35-41, 1995.
15. Dnistrian AM, Schwartz MK, Greenberg EJ and Schwartz DC: BR27.29 as a marker in breast cancer. J Tumor Marker Oncology 10: 91-97, 1995.
16. Dnistrian AM, Schwart, MK, Greenberg EJ, Smith CA and Scharwartz DC: CA 15-3 and carcinoembryonic antigen in the clinical evaluation of breast cancer. Clin Chem Acta 200: 81-93, 1991.
17. Eskelinen M, Hippelainen M, Kettunen J, Salmela E, Pentila I and Alhava E: Clinical value of serum tumor markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis: Results from a prospective study. Anticancer Res 14: 699-703, 1994.
18. Hayes DF: Serum (circulating) tumor markers for breast cancer: recent results. Cancer Res 40: 101-113, 1996.
19. Kiang, DT, Greenberg LJ and Kennedy BJ: Tumor marker kinetics in the monitoring of breast cancer. Cancer 65: 193-199, 1990.
20. van Dalen A: New markers for breast carcinoma-associated antigen in comparison with CA 15-3. Anticancer Res 16: 2339-2343, 1996.
21. Sonoo H and Kurebayashi J: Serum tumor marker kinetics and the clinical course of patients with advanced breast cancer. Surg Today Jpn J Surg 26: 250-257, 1996.
22. Gold P and Freeman SO: Specific carcinoembryonic antigens of the human digestive system. J Exp Med 722: 467-481, 1965.
23. Holzel WG, Beer R, Deschner W, Griesmacher A and Muller MM: Individual reference ranges of CA 15-3, MCA and CEA in recurrence of breast cancer. Scand J Clin Lab Invest Suppl 221: 93-101, 1995.
24. Fernandez-Pol JA: Growth factors, oncogenes, and aging. In: Balducci L, Lyman GH and Ershler WB (eds) Comprehensive geriatric oncology, Harwood Academic Publishers, Amsterdam, 2004, pp 179-196 (in press).
25. Fernandez-Pol JA: Metallopanstimulin as a novel tumor marker in sera of patients with various types of common cancers: implications for prevention and therapy. Anticancer Res 16: 2177-2186, 1996.
26. Fernandez-Pol JA: Modulation of EGF receptor protooncogene expression by growth factors and hormones in human breast carcinoma cells. CRC Critical Reviews in Oncogenesis 2: 173-185, 1991.
27. Fernandez-Pol JA, Fletcher JW, Hamilton PD and Klos DJ: Expression of metallopanstimulin and oncogenesis in human prostatic carcinoma. Anticancer Res 17: 1519-1530, 1997.
28. Fernandez-Pol JA, Klos DJ and Hamilton PD: Metallopanstimulin gene product produced in a baculovirus expression system is a nuclear phosphoprotein that binds to DNA. Cell Growth Differentiation 5: 811-825, 1994.
29. Fernandez-Pol JA, Klos DJ and Hamilton PD: A growth factor-inducible gene encodes a novel nuclear protein with zinc-finger structure. J Biol Chem 268: 21198-21204, 1993.
30. Fernandez-Pol JA, Hamilton PD and Klos DJ: Essential viral and cellular zinc and iron containing metalloproteins as targets for novel antiviral and anticancer agents: Implications for prevention and therapy of viral diseases and cancer. Anticancer Res 21: 931-57, 2001.
31. Fernandez-Pol JA and Douglas MG: Molecular Interactions of Cancer and Age. In: Balducci L and Extermann M (eds) Cancer in the elderly, current concepts and future directions. Hematology / Oncology Clinics of North America, Saunders WB Co, Philadelphia, 2000, Vol 14, No. 1, pp. 25-44.
32. Revenkova E, Masson J, Koncz C, Koncz C, Alfasar K, Jakovleva and Paszkowski J: Involvement of Arabidopsis thaliana ribosomal protein S27 in mRNA degradation triggered by genotoxic strees. The EMBO Journal 18: 101-110, 1999.
33. Santa Cruz DJ, Hamilton PD, Klos DJ and Fernandez-Pol JA: Differential expression of metallopanstimulin/S27 ribosomal protein in melanocytic lesions of the skin. J Cutan Patho 24: 533-542, 1997.
34. Atsuka Y, Aoki N, Sato K, Oikawa K, Nochi H, Miyokawa N, Hirata S, Kimura S, Sasajima T and Katagiri M: Identification of metallopanstimulin-1 as a member of a tumor associated antigen in patients with breast cancer. Cancer Letters 182: 101-107, 2002.
35. Ganger DR, Hamilton PD, Klos DJ, Jakate S, McChesney L and Fernandez-Pol JA: Differential Expression of Metallopanstimulin/S27 ribosomal protein in 'hepatic regeneration and neoplasia. Cancer Detection and Prevention 25: 241-246, 2001.
36. Xynos FP, Klos DJ, Hamilton PD, Schuette V, Huygens P and Fernandez-Pol JA: Expression of metallopanstimulin in condylomata acuminata of the female anogenital region induced by papilloma virus. Anticancer Res 14: 773-786, 1994.
37. Sundblad AS, Ricci L, Xynos FP, Hamilton PD, Klos DJ and Fernandez-Pol JA: Metallopanstimulin-1/S27 Ribosomal antigen expression in stages I and II breast cancer: Its relationship with Clinicopathological Factors. Cancer, Genomics and Proteomics, ------, 2005.
38. Knight WS, Hannon WH, Ivor L, Johnson AM, Josepth JM, Nakamura RM, O'Brien TA, Ritchie RF, Tourville DR, Tripodi D and Vadlamudi S: Assessing the Quality of Radioimmunoassay Systems. NCCLS document LA1-A2, Vol. 14, pp 1-23. NCCLS, Villanova, PA, 1994.
39. Sacket, DL, Haynes RB, Guyatt GH and Tugwell P: Clinical epidemiology: A basic science for clinical medicine. Little, Brown and Co, Boston, Toronto, London, 1991, 2nd edition, pp 69-185.
40. Jaeschke R, Guiyatt GH and Sackett DL: Evidence-based medicine working group. User's guides to the medical literature, III: how to use an article about a diagnostic test, A: are the results of the study valid?. JAMA 277: 389-391, 1994.
41. Ali SM, Leitzel K, Chinchilli VM, Engle L, Demers L, Harvey HA, Carney W, Allard JW and Lipton A: Relationship of serum HER-2/neu and serum CA 15-3 in patients with metastatic breast cancer. Clin. Chem 48: 1314-20, 2002
42. Kokko R, Holli K and Hakama M: CA 15-3 in the follow-up of localized breast cancer: a prospective study. Eur J Cancer 38: 1165-6, 2002.
43. Vaarala M, Porvari KS, Kyllonen AP, Mustonen MVJ, Kukkarinen O and Vihko PT: Several genes encoding ribosomal proteins are overexpressed in prostate cancer cell lines: Confirmation of L7a and L37 over-expression in prostate cancer tissue samples. Int J Cancer 78: 27-32, 1998.
44. Kerlikowske K, Grady D, Barclay J, Sickles EA and Ernster V: Effect of age, breast density, and family history on the sensitivity of first screening mammography. JAMA 276: 33-38, 1996a.
45. Kerlikowske K, Grady D, Barclay J, Sickles EA and Ernster V: Likelihood ratios for modern screening mammography: Risk of breast cancer based on aged and mammographic interpretation. JAMA 276: 39-43, 1996b.
46. Wulfkuhle JD, Sgroi DC, Krutzch H, McLean K, McGarvey K, Knwolton M, Chen S, Shu H, Sahin A, Kurek R, Wallwiener D, Merino MJ, Petricoin EF, Zhao Y and Steeg PS: Proteomics of human breast ductal carcinoma in situ. Cancer Res 62: 6740-6749, 2002.
47. Tyers M and Mann M: From genomics to proteomics. Nature 422: 193-197, 2003.
48. Aebersold R and Mann M: Mass-spectrometry-based proteomics. Nature 422: 198-207, 2003.
49. Hanash S: Disease Proteomics. Nature 422: 226-232, 2003.
50. Watkins B et al: Detection of early-stage cancer by serum proteomic analysis. American Laboratory 1: 32-36, 2001.
51. de Bruun MHL and Fey GH: Human complement component C3: cDNA coding sequence and derived primary structure. Proc Natl Acad Sci USA 82: 708-712, 1985.
52. Kitano E and Kitamura H: Synthesis of the third component of complement (C3) by human gastric cancer-derived cell lines. Clin. & Exper. Immunol 94: 273-278, 1993.
53. Kurosky A et al: Alpha 1S sequence of haptoglobin. Proc Natl Acad Sci USA 77: 3388-3392, 1980.
54. Ye B et al: Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: Identification and characterization by using proteomic profiling and mass spectrometry. Clin Cancer Res 9: 2904-2911, 2003.
55. Stack Jr, Dalsaso T, Lee Jr C, Lowe VJ, Hamilton PD, Fletcher JW and Fernandez-Pol JA: Overexpression of MPS antigens by squamous cell carcinomas of the head and neck: Immunohistochemical and serological correlation with FDG Positron Emission Tomography. Anticancer Res 19: 5503-5510, 1999.
56. Wadsworth JT et al: Identification of Patients with head and neck cancer using serum protein Profiles. Arch Otolaryngol Head Neck Sur 130: 98-104, 2004.
57. Lee WJ et al: A new assay for head and neck squamous cell carcinoma using the tumor marker Metallopanstimulin. Otolaryngol Head Neck Surg 131: 466-471, 2004.
58. Losh S, Buchholz M, Gress TM and Weidle UH: Identification of a novel transmembrane protein (UKW): Association with invasive status of mammary carcinoma cell lines and expression in pancreatic carcinoma. Cancer Genomics & Proteomics 1: 263-274, 2004.
59. Fernandez-Pol JA and Fletcher JW: Novel MPS-H proteins as serological markers for breast cancer. Cancer Detection and Prevention 22/Supplement 1, S209-abs 535, 1998.61.
60. Lui VWY and Grandis JR: EGFR-Mediated cell cycle regulation. Anticancer Res 22: 1-12, 2002.
61. Barbieri MA, Ramkumar TP, Fernandez-Pol S(Sebastian), Chen PI and Stahl PD: Receptor tyrosine kinase signaling and trafficking: Paradigms Revisited. In: Signalling from internalized Growth Factor Receptors, IH Madshus (Ed.), Springer-Verlag 2004, CTMI 286: 1-20, 2004.
62. Fernandez-Pol JA: Essential viral and cellular zinc and iron containing metalloproteins as targets for novel antiviral and anticancer agents: Implications for prevention and therapy of viral diseases and cancer. Anticancer Res 21: 931-958, 2001.
63. Janssen D: Looking beyond the human genome: The Human Proteome Organization (HUPO) has been making progress in its global activities to study the human proteome. Genomics and Proteomics, June 2003:36-39.
64. Morley BJ and Walport MJ: The Complement Facts Book. Academic Press, San Diego,CA, pp. 1-221, 2000.
65. Morgan BP and Harris CL: Complement regulatory proteins. Academic Press, San Diego,CA, pp. 1-370, 1999.
66. Fernandez-Pol JA: Genomics, Proteomics and Cancer: Specific ribosomal, mitochondria, nuclear and tumor reactive proteins can be used as biomarkers for early detection of breast cancer. Anticancer Research 24: 3484; Abs. 149. 7th International Conference of Anticancer Research, 25-30 October 2004, Corfu, Greece.